- Home
- KLRS vs BDL Comparison
KLRS vs BDL Comparison
Compare KLRS & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- BDL
- Stock Information
- Founded
- KLRS 2019
- BDL 1959
- Country
- KLRS United States
- BDL United States
- Employees
- KLRS N/A
- BDL N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- BDL Restaurants
- Sector
- KLRS Health Care
- BDL Consumer Discretionary
- Exchange
- KLRS Nasdaq
- BDL Nasdaq
- Market Cap
- KLRS 46.0M
- BDL 52.7M
- IPO Year
- KLRS N/A
- BDL N/A
- Fundamental
- Price
- KLRS $4.39
- BDL $29.50
- Analyst Decision
- KLRS Strong Buy
- BDL
- Analyst Count
- KLRS 2
- BDL 0
- Target Price
- KLRS $23.00
- BDL N/A
- AVG Volume (30 Days)
- KLRS 728.6K
- BDL 1.6K
- Earning Date
- KLRS 11-15-2025
- BDL 08-12-2025
- Dividend Yield
- KLRS N/A
- BDL 1.83%
- EPS Growth
- KLRS N/A
- BDL 41.91
- EPS
- KLRS N/A
- BDL 2.32
- Revenue
- KLRS N/A
- BDL $201,851,000.00
- Revenue This Year
- KLRS N/A
- BDL N/A
- Revenue Next Year
- KLRS N/A
- BDL N/A
- P/E Ratio
- KLRS N/A
- BDL $11.90
- Revenue Growth
- KLRS N/A
- BDL 8.84
- 52 Week Low
- KLRS $2.14
- BDL $22.61
- 52 Week High
- KLRS $24.15
- BDL $35.98
- Technical
- Relative Strength Index (RSI)
- KLRS 58.92
- BDL 51.02
- Support Level
- KLRS $3.49
- BDL $26.33
- Resistance Level
- KLRS $5.30
- BDL $30.75
- Average True Range (ATR)
- KLRS 0.77
- BDL 0.89
- MACD
- KLRS -0.01
- BDL 0.01
- Stochastic Oscillator
- KLRS 23.97
- BDL 67.74
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.